$MTWO
M2i Global, Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223036618 Filed on October 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.446M $23.36K
YoY Change 6090.71%
Operating Profit -$1.446M -$23.36K
YoY Change 6090.71%
Interest Expense $23.36K
YoY Change 1291.54%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.446M $23.36K
YoY Change -6290.71% 1291.54%
Income Tax
% Of Pretax Income
Net Earnings -$1.446M -$23.36K
YoY Change 6090.71%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 514.3M shares 514.3M shares 5.092M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $48.20K $44.91K $114.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $13.97K
Receivables
Other Receivables
Total Short-Term Assets $48.20K $44.91K $14.08K
YoY Change 247.22% 218.97%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $6.370K
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $48.20K $44.91K $14.08K
Total Long-Term Assets $0.00 $0.00 $6.370K
Total Assets $48.20K $44.91K $20.45K
YoY Change -61.7% 119.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.869K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.087M $1.109M $88.64K
YoY Change 789.28% 1150.8%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.087M $1.109M $88.64K
Total Long-Term Liabilities
Total Liabilities $1.087M $1.109M $88.64K
YoY Change 789.28% 1150.8%
SHAREHOLDERS EQUITY
Retained Earnings -$2.114M -$2.137M $105.0K
YoY Change -1808.09% -2136.44%
Common Stock $514.3K $514.3K $5.092K
YoY Change 7139.04% 10000.82%
Preferred Stock
YoY Change
Treasury Stock (at cost) $435.0K $435.0K
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.039M -$1.064M -$68.19K
YoY Change
Total Liabilities & Shareholders Equity $48.20K $44.91K $20.45K
YoY Change -61.7% 119.62%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$1.446M -$23.36K
YoY Change 6090.71%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001753373
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
usd
CY2023Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
usd
us-gaap Revenues
Revenues
usd
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
MTWO Asset Impairment Charge
AssetImpairmentCharge
usd
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
MTWO Contribution From Settlement Of Related Party Liabilities
ContributionFromSettlementOfRelatedPartyLiabilities
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-08-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-229748
dei Entity Registrant Name
EntityRegistrantName
M2i GLOBAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-1904036
dei Entity Address Address Line1
EntityAddressAddressLine1
885 Tahoe Blvd.
dei Entity Address City Or Town
EntityAddressCityOrTown
Incline Village
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89451
dei City Area Code
CityAreaCode
(775)
dei Local Phone Number
LocalPhoneNumber
909-6000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
514333691 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44914 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13767 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
44914 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13881 usd
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
111970 usd
CY2023Q3 us-gaap Assets
Assets
44914 usd
CY2022Q4 us-gaap Assets
Assets
125851 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
908748 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
476 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
49000 usd
CY2023Q3 us-gaap Loans Payable Current
LoansPayableCurrent
200000 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
72774 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1108748 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
122250 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1108748 usd
CY2022Q4 us-gaap Liabilities
Liabilities
122250 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
100000 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
100000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
100 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
514333691 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
514333691 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7105357 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7105357 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
514334 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7105 usd
CY2023Q3 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
30975 usd
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
435000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1024995 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
120255 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2137288 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123759 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1063834 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3601 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44914 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125851 usd
us-gaap Revenues
Revenues
3400 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1446398 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23364 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1921863 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
47635 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1446398 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
23364 usd
us-gaap Operating Expenses
OperatingExpenses
1921863 usd
us-gaap Operating Expenses
OperatingExpenses
47635 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1446398 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23364 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1918463 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-47635 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
94952 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-114 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1446398 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23364 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2013529 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47635 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1446398 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23364 usd
us-gaap Net Income Loss
NetIncomeLoss
-2013529 usd
us-gaap Net Income Loss
NetIncomeLoss
-47635 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
514333691 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5092023 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
205183575 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5092023 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3601 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-27991 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-24390 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
977828 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-435000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
146593 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-539140 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
125891 usd
CY2023Q3 MTWO Stock Issued During Period Value Cash Received For Subscription Receivable
StockIssuedDuringPeriodValueCashReceivedForSubscriptionReceivable
256673 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1446398 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1063834 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-20557 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11501 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-32058 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12770 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-44828 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-44828 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23364 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-68192 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-68192 usd
us-gaap Net Income Loss
NetIncomeLoss
-2013529 usd
us-gaap Net Income Loss
NetIncomeLoss
-47635 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
20503 usd
MTWO Asset Impairment Charge
AssetImpairmentCharge
94952 usd
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
114 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-13767 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5375 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
912991 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
250 usd
us-gaap Increase Decrease In Due To Other Related Parties
IncreaseDecreaseInDueToOtherRelatedParties
16500 usd
us-gaap Increase Decrease In Due To Other Related Parties
IncreaseDecreaseInDueToOtherRelatedParties
31500 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-954702 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10510 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
6310 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6310 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1234501 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
435000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
200000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
16880 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
999501 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16880 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
44800 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
114 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
114 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44914 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
114 usd
MTWO Contribution From Settlement Of Related Party Liabilities
ContributionFromSettlementOfRelatedPartyLiabilities
146593 usd
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
100000 shares
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_zRf9zZAcB8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z9W5ENsnrazl">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
94952 usd
CY2023Q2 MTWO Share Authorized
ShareAuthorized
1000100000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
1 vote per share
CY2023Q3 MTWO Subscription Receivable
SubscriptionReceivable
30975 usd
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
514333691 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
514333691 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
100000 shares

Files In Submission

Name View Source Status
0001493152-23-036618-index-headers.html Edgar Link pending
0001493152-23-036618-index.html Edgar Link pending
0001493152-23-036618.txt Edgar Link pending
0001493152-23-036618-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
mtwo-20230831.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mtwo-20230831_def.xml Edgar Link unprocessable
mtwo-20230831_lab.xml Edgar Link unprocessable
mtwo-20230831_cal.xml Edgar Link unprocessable
mtwo-20230831_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed